Ones To Watch News
Refine Search
Biotechnology
US biopharma firm Eiger BioPharmaceuticals saw its shares plummet more than 40% to $0.41, after it announced its decision to discontinue the Phase III LIMT-2c study of peginterferon lambda in patients with chronic hepatitis delta (CHD). 14 September 2023
Biotechnology
Stock in New Jersey, USA-based Rocket Pharmaceuticals shot up around 40% on Wednesday, following good news on the financing and regulatory fronts. 14 September 2023
Biotechnology
In France, a recently-founded biotech focused on the tumor microenvironment has agreed terms for a licensing and co-development program with SATT Nord. 14 September 2023
Biotechnology
Shares of London-listed blood disease specialist Hemogenyx Pharmaceuticals were up more than 9% at 1.80 pence, after it revealed in a stock exchange filing a positive development for its investigational product. 14 September 2023
Biotechnology
UK biotech start-up Myricx Bio today announced the appointment of Dr Robert McLeod as vice president clinical development. 13 September 2023
Biotechnology
US immunology specialist Acelyrin lost a whopping 54% of its stock market value on Tuesday. 13 September 2023
Pharmaceutical
US genomics-based drug discovery company Exelixis has entered into an exclusive license agreement with Sino-American firm Insilico Medicine for global rights to develop and commercialize the latter’s ISM3091. 13 September 2023
Biotechnology
US biotech start-up Septerna says it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals under which Vertex has acquired an undisclosed discovery-stage GPCR program. 13 September 2023
Biotechnology
US cell and gene therapy biotech 2seventy bio had a bumpy ride this morning, after it announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. 12 September 2023
Biotechnology
Chinese biopharma Hutchmed today announced positive results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (MET) exon 14 skipping alteration non-small cell lung cancer (NSCLC). 12 September 2023
Biotechnology
Privately-held Swedish firm Salipro Biotech has entered into a research collaboration with Japan's Sumitomo Pharma to reveal the mechanism of action and pharmacological characterization of a drug candidate. 12 September 2023
Biotechnology
Neumora Therapeutics, a Phase III US biotech developing therapies for brain diseases, announced terms for its initial public offering (IPO) on Monday. 12 September 2023
Pharmaceutical
US clinical-stage liver disease drug developer Madrigal Pharmaceuticals today announced that Bill Sibold has succeeded Dr Paul Friedman as the firm’s chief executive and joined Madrigal’s board of directors. 11 September 2023
Pharmaceutical
Florida, USA-based biotech Veru has expressed its confidence in breast cancer candidate enobosarm, citing data from a discontinued Phase III trial. 11 September 2023
Biotechnology
German drug developer Immatics saw its shares rise as much as 6.6% to $12.98 pre-market, after its announced a strategic research and development collaboration with US biotech Moderna. 11 September 2023
Pharmaceutical
Shares of US drug developer Crinetics Pharmaceuticals shot up more than 66%% to $26.60 pre-market, after its experimental treatment for a rare hormonal disorder not only succeeded, but performed better than Wall Street expectations. 11 September 2023
Biotechnology
Swiss ophthalmology firm Oculis Holding today announced the appointment of Rebecca Weil to the role of chief commercial officer. 11 September 2023
Pharmaceutical
Boston, USA-based Glyscend Therapeutics, which is developing a revolutionary approach to treating type 2 diabetes, has appointment of Sapan Shah as chief executive (CEO). 8 September 2023
Biotechnology
Japanese mid-size drugmaker Otsuka Pharmaceutical has inked a deal with ShapeTX, a specialist in programmable medicines. 8 September 2023
Pharmaceutical
US biopharma CymaBay Therapeutics traded up as much as 21% to $16.73 yesterday, as the company released encouraging trial results for its primary biliary cholangitis (PBC) candidate after earlier disappointments. 8 September 2023
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze